Literature DB >> 8897168

Comparison of a competitive combined reverse transcription-PCR assay with a branched-DNA assay for hepatitis C virus RNA quantitation.

C Mayerat1, P Bürgisser, D Lavanchy, A Mantegani, P C Frei.   

Abstract

We have developed a sensitive and reproducible one-step competitive reverse transcriptase (RT) PCR assay, which allows hepatitis C virus (HCV) RNA quantitation in plasma over a broad range of values. The RNA samples and a constant amount of an internal standard were reverse transcribed and coamplified with the same primers in the same tube. A standard curve was obtained from an additional series of tubes containing both the internal standard and known amounts of a wild-type HCV RNA transcript, thus eliminating the need for titrating samples with the competitor. Eighty-eight anti-HCV-positive samples were tested by RT-PCR and a branched-DNA (bDNA) assay which has a detection limit of 3.5 x 10(5) copies per ml. Fifty-five samples were quantifiable by both methods (correlation coefficient, 0.72), the ranges of values found by the RT-PCR and bDNA assays being, respectively, 0.127 x 10(6) to 18.4 x 10(6) and 0.44 x10(6) to 38 x 10(6) copies per ml. Six samples that had indeterminate values by the bDNA assay had RT-PCR values between 0.37 x 10(5) and 9.6 x 10(5) copies per ml. Twenty-two samples that had values below the cutoff value by the bDNA assay had RT-PCR values between 2.5 x 10(3) and 10.4 x 10(5) (18 less than and 4 more than the limit of 3.5 x 10(5) copies per ml). The remaining five samples were negative by both assays. The level of RT-PCR interassay reproducibility was high (correlation coefficient between duplicate values, 0.94). Our method, with a detection limit of 2,500 copies per ml, was markedly more sensitive than the bDNA assay. This method is convenient for following up patients with low viremia, a common situation with alpha interferon treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897168      PMCID: PMC229389          DOI: 10.1128/jcm.34.11.2702-2706.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Enhanced detection by PCR of hepatitis C virus RNA.

Authors:  J A Garson; C Ring; P Tuke; R S Tedder
Journal:  Lancet       Date:  1990-10-06       Impact factor: 79.321

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Implications of variations of "conserved" regions of hepatitis C virus genome.

Authors:  J Y Lau; P Simmonds; M S Urdea
Journal:  Lancet       Date:  1995-08-12       Impact factor: 79.321

4.  Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.

Authors:  A M Di Bisceglie; P Martin; C Kassianides; M Lisker-Melman; L Murray; J Waggoner; Z Goodman; S M Banks; J H Hoofnagle
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

5.  Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications.

Authors:  D R Gretch; C dela Rosa; R L Carithers; R A Willson; B Williams; L Corey
Journal:  Ann Intern Med       Date:  1995-09-01       Impact factor: 25.391

6.  Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease.

Authors:  D Gretch; L Corey; J Wilson; C dela Rosa; R Willson; R Carithers; M Busch; J Hart; M Sayers; J Han
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

7.  Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France.

Authors:  P Marcellin; N Boyer; E Giostra; C Degott; A M Courouce; F Degos; H Coppere; P Cales; P Couzigou; J P Benhamou
Journal:  Hepatology       Date:  1991-03       Impact factor: 17.425

8.  Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C.

Authors:  E Orito; M Mizokami; T Nakano; H Terashima; O Nojiri; K Sakakibara; M Mizuno; M Ogino; M Nakamura; Y Matsumoto
Journal:  J Med Virol       Date:  1994-12       Impact factor: 2.327

9.  Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C.

Authors:  T Aiyama; K Yoshioka; H Hirofuji; A Kusakabe; M Yamada; K Tanaka; S Kakumu
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

10.  Preparation and characterization of RNA standards for use in quantitative branched DNA hybridization assays.

Authors:  M L Collins; C Zayati; J J Detmer; B Daly; J A Kolberg; T A Cha; B D Irvine; J Tucker; M S Urdea
Journal:  Anal Biochem       Date:  1995-03-20       Impact factor: 3.365

View more
  4 in total

1.  Hepatitis C virus quantitation: optimization of strategies for detecting low-level viremia.

Authors:  W T Hofgärtner; J A Kant; K E Weck
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Transcriptional profiling of TLR-4/7/8-stimulated guinea pig splenocytes and whole blood by bDNA assay.

Authors:  Lance K Ching; Farah Mompoint; Jeffrey A Guderian; Alex Picone; Ian M Orme; Rhea N Coler; Steven G Reed; Susan L Baldwin
Journal:  J Immunol Methods       Date:  2011-08-03       Impact factor: 2.303

3.  Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response.

Authors:  Kathie-Anne Walters; Michael A Joyce; Jill C Thompson; Maria W Smith; Matthew M Yeh; Sean Proll; Lin-Fu Zhu; T J Gao; Norman M Kneteman; D Lorne Tyrrell; Michael G Katze
Journal:  PLoS Pathog       Date:  2006-06-23       Impact factor: 6.823

4.  Genomic analysis reveals a potential role for cell cycle perturbation in HCV-mediated apoptosis of cultured hepatocytes.

Authors:  Kathie-Anne Walters; Andrew J Syder; Sharon L Lederer; Deborah L Diamond; Bryan Paeper; Charles M Rice; Michael G Katze
Journal:  PLoS Pathog       Date:  2009-01-16       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.